Cognizin Influences Brain Wave Activity Alongside Cognitive Performance: Study

Kyowa Hakko will present new research on Cognizin Citicoline at the upcoming International Society of Sports Nutrition (ISSN) annual conference. The study looked at the acute single-dose effects of Cognizin on brain wave activity and cognitive performance in healthy adults.

Cognizin has been studied for decades for its roles in focus, mental energy, attention, and memory. While benefits are established following extended supplementation, the new study sought to determine whether a single dose could affect meaningful changes in cognitive function and neuroelectric activity.

 The study evaluated a 500 mg dose of Cognizin versus a placebo in healthy men, measuring outcomes across electroencephalogram (EEG) brain wave analysis, validated cognitive performance tasks, and subjective mood and affect assessments. Participants were evaluated at 60 minutes and 240 minutes post-ingestion, providing insight into the onset and duration of potential cognitive effects.

“This study is an exciting step forward for the Cognizin research portfolio,” said Katie Emerson, PhD, senior manager of scientific affairs at Kyowa Hakko USA. “By exploring the acute effects of a single dose, we’re gaining new insight into how quickly Cognizin may begin to support brain function, which has meaningful implications for product development across cognitive health, sports nutrition, and functional food and beverage applications.”

The complete study findings, including a dive into the study methodology, neurophysical findings, and the future of cognitive health ingredient science will be revealed at the 2026 ISSN Annual Conference in a 30-minute presentation, “Fueling Focus: Acute Cognizin Effects on Brain Activity and Cognitive Performance.” The session will be presented by Emerson and Tim N. Ziegenfuss, PhD, CSCS, FISSN, CEO of the Center for Applied Health Sciences and past president of ISSN.